Back to search results

Research Study Comparing Doses of NNC0662-0419 for Type 2 Diabetes

This research study is looking at how well different doses of a new medicine, NNC0662-0419, work to lower blood sugar in people with type 2 diabetes. It also checks how safe NNC0662-0419 is compared to a placebo (an inactive substance) or semaglutide, an approved diabetes medicine. Participants will receive NNC0662-0419, semaglutide, or a placebo, decided by chance. The main goal is to see how much NNC0662-0419 changes your HbA1c (a measure of average blood sugar over time) after 16, 28, and 40 weeks. You might be able to join if you are 18-75 years old and have an HbA1c between 7.0% and 10.0%. The study is currently unclear on its recruitment status and plans to enroll 270 people.

Study design
This is an interventional study comparing different doses of NNC0662-0419 to semaglutide and placebo. Participants are assigned to a treatment by chance, and about 270 people are planned to be included.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Your HbA1c will be measured at 16, 28, and 40 weeks after starting the study, to see how well the treatment is working.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07415954

A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 Diabetes

Recruiting
PHASE2Ages 18–75InterventionalTreatment
Novo Nordisk A/S
~270 participants
Updated 2026-08-10 on ClinicalTrials.gov
What's tested:NNC0662-0419SemaglutidePlacebo

At a glance

Recruiting sites
55 of 63 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Change in glycated haemoglobin (HbA1c) (week 16)
Measured over From baseline (week 0) to week 16
+2 more outcomes measured

Conditions

Diabetes Mellitus, Type 2

Explore related trials

Type 2 Diabetes Mellitus

Where it's being run

63 sites across 26 states
California6
Florida5
Japan5
Spain5
Thailand5
Croatia4
Poland4
Portugal4

Study leadership

  • Clinical Transparency (dept. 2834) · STUDY_DIRECTOR · Novo Nordisk A/S

Who to contact

Novo Nordisk
[email protected]
(+1) 866-867-7178
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Male or female (sex at birth).
Age 18-75 years (both inclusive) at the time of signing the informed consent.
Glycated haemoglobin (HbA1c) of 7.0-10.0 percent (%) (53-86 millimoles per mole \[mmol/mol\]) (both inclusive) as assessed by central laboratory at screening.
Willingness to obtain a high weight loss (greater than \[\>\] 25% of weight at baseline).
Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Pharmacological pupil-dilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination.
Known hypoglycaemic unawareness as indicated by the investigator according to Clarke's Questionnaire.

What this trial measures

  • Change in glycated haemoglobin (HbA1c) (week 16)From baseline (week 0) to week 16

    Measured as percentage-point (%-point).

  • Change in HbA1c (week 28)From baseline (week 0) to week 28

    Measured as %-point.

  • Change in HbA1c (week 40)From baseline (week 0) to week 40

    Measured as %-point.